Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
126. |
ECCT/21/02/03 | VAC078 A Phase III randomized, controlled, multi-centre trial to evaluate the efficacy of the R21/Matrix-M vaccine in African children against clinical malaria. |
Principal Investigator(s) 1. Mainga Patience Mayeso Hamaluba 2. Jean Bosco Ouedraogo 3. Halidou Tinto 4. Alassane Dicko 5. Ally Olotu Site(s) in Kenya KEMRI Wellcome Trust Research Programme |
View |
127. |
ECCT/24/05/03 | SIBP-MMR-02 A Phase III, Multi-Center, Randomized, Observer-Blind, Active Controlled Non-Inferiority Study to Evaluate the Immunogenicity and Safety of Shanghai Institute of Biological Products Co., Ltd.’s Measles, Mumps and Rubella (MMR) Vaccine Compared to a Licensed and WHO Prequalified GSK MMR Vaccine in Healthy African Children, 9- 11 Months of Age |
Principal Investigator(s) 1. Dr Walter Otieno 2. Dr. Diana Odhiambo Site(s) in Kenya 1. Victoria Biomedical Research Institute (Kisumu county) 2. Victoria Biomedical Research Institute (Kisumu county) 3. Victoria Biomedical Research Institute (Kisumu county) |
View |
128. |
ECCT/24/11/01 | Sparkle A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises |
Principal Investigator(s) 1. Lucas Otieno Tina Site(s) in Kenya 1. Site 1401:Victoria Biomedical Research Institute (Kisumu county) 2. Site 1402:Ahero Clinical trials Unit (Kisumu county) 3. Site 1403:International Cancer institute (Uasin Gishu county) 4. Site 1404:Kondele Childrens Hospital (Kisumu county) 5. Site 1405:KEMRI/CRDR KEMRI Clinical Research Annex (Kisumu county) 6. Site 1406:Gertrudes Children’s Hospital (Nairobi City county) |
View |
129. |
ECCT/25/03/07 | Sparkle - Site 1405 A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises |
Principal Investigator(s) 1. Prof Videlis Nduba Site(s) in Kenya 1. KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county) 2. Ahero Clinical trials Unit (Kisumu county) 3. International Cancer institute (Uasin Gishu county) 4. Kondele Childrens Hospital (Kisumu county) 5. Gertrudes Children’s Hospital (Nairobi City county) 6. Victoria Biomedical Research Institute (Kisumu county) |
View |
130. |
ECCT/11/08/03 | Compare the Efficacy and Safety of Gentian Violet to that of Nystatin A Phase III, Open-Label, Randomized, Assessment-Blinded Clinical Trial to Compare the Safety and Efficacy of Topical Gentian Violet to that of Nystatin Oral Suspension for the Treatment of Oropharyngeal Candidiasis in HIV-1 Infected Participants in Non-U.S. Settings |
Principal Investigator(s) 1. Deborah C Langat Site(s) in Kenya 1. Kenya Medical Research Institute Walter Reed Project Clinical Research Centre (Kericho county) 2. Moi University Clinical Research Centre (Uasin Gishu county) |
View |